Endologix (ELGX +1.8%) pipeline looks impressive, says Oppenheimer. After meeting with management, the firm says ELGX's growth story remains intact and that abdominal aortic aneurysm market volumes and pricing remain solid. The firm thinks the Street is still underestimating the value of the company's Nelix treatment and reiterates a Buy on the stock.
From other sites
at CNBC.com (Feb 28, 2014)
at CNBC.com (Dec 5, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs